At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
Lidocaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spasmodic Dysphonia Pain Study
In Brief
A Phase 3 clinical trial evaluating Lidocaine and Vibrating wand for Spasmodic Dysphonia. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This study aims to identify adjuvant methods to improve patient comfort during in-office laryngology procedures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpasmodic Dysphonia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartAug 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedDec 2, 2020
Enrollment StartAug 1, 2021
Primary CompletionJul 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.6 years ago
Interventions
Lidocainedrug
Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine
Vibrating wanddevice
a vibrating instrument held adjacent to the cricothyroid space